BriaCell Therapeutics Corp. ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announces that on January 24, 2025 (the ...
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...
(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK ... Monday's Regular trading at $70.08 up $1.02 or 1.48%. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are ...
An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...
Daiichi Sankyo’s Vanflyta has become the first drug ... in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl ...
Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback